About ITM
ITM is a vertically integrated biotechnology company dedicated to advancing precision oncology through radioisotopes and radiopharmaceutical innovation. Over more than two decades, we have built integrated capabilities spanning isotope production, manufacturing, and clinical development to help expand access to targeted cancer therapies.
Today, our radiopharmaceutical business is advancing under Lumara Bio, an ITM company, which is focused on developing the next generation of targeted radiopharmaceutical therapies for cancers with significant unmet need.
At the same time, ITM continues to strengthen its position as a leading global supplier of medical radioisotopes, expanding the manufacture and supply of novel isotopes, including non-carrier-added Lutetium-177 (n.c.a. Lu-177) and Actinium-225 (Ac-225), to support patients and partners worldwide.
From advanced diagnostics to potentially life-changing treatments, every step we take is guided by our commitment to transforming patient care - delivering treatment options and clinical solutions for today and the future.
Our Mission
We aim to provide highly precise radiodiagnostics and radiotherapeutics for the identification and treatment of cancers with a high unmet need. We are leveraging our longstanding radioisotope leadership to build a broad precision oncology pipeline to improve clinical outcomes and quality of life for people living with cancer.
Our Vision
Every aspect of ITM’s organization, from isotope production to radiopharmaceutical development, is designed with one goal in mind: delivering effective, targeted treatment options that can positively contribute to patients’ quality of life.
Our History
Advancing Radiopharmaceutical Innovation
For over two decades, we have proudly contributed to the evolution of radiopharmaceuticals through our expertise in isotope manufacturing and radiopharmaceutical development. With a vertically integrated approach, we supply medical radioisotopes while advancing a deep and robust pipeline, including late-stage programs with differentiated approaches to clinically validated targets and early-stage novel programs.
